Skip to main content
Premium Trial:

Request an Annual Quote

Evotec Inks Deal with Apeiron to Use Chemical Proteomics in Cancer Drug Development

Premium

German pharmaceutical firm Evotec said this week that it has entered a research collaboration with Apeiron Biologics in which it will apply its chemical proteomic capabilities to the development of immunomodulatory compounds to treat cancer.

The agreement stems from a successful high-throughput phenotypic screen previously performed for Apeiron by Evotec, the company said in a statement.

Evotec obtained its chemical proteomics assets through its 2011 purchase of proteomics firm Kinaxo Biotechnologies for €16 million ($22 million). Kinaxo, which was spun out of the Max Planck Institute by researchers including Matthias Mann, used mass-spec-based competition binding assays to profile small molecule drugs and drug targets.

In June 2011, Evotec signed a deal with Roche to use the technology to identify biomarkers for oncology drugs in Roche's pipeline (PM 7/1/2011). Prior to the acquisition, Kinaxo had collaborations ongoing with pharma firms including Takeda and AstraZeneca.

Apeiron is a Vienna-based biotech firm with five current clinical programs, including projects developing therapies for neuroblastoma and inflammation.

Financial and other details of the agreement were not provided.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.